Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Academic Centers Are Associated with Improved Survival Outcomes in High Risk Diffuse Large B-Cell Lymphoma Patients

Daniel A. Ermann, MD, Victoria Vardell Noble, Avyakta Kallam, MBBS, James O. Armitage, MD

Blood (2018) 132 (Supplement 1): 4747.

https://doi.org/10.1182/blood-2018-99-115578

Published: 2018

Journal Articles

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Avyakta Kallam, MBBS, Jane Meza, PhD, Philip Bierman, MD, Matthew A. Lunning, DO, R. Gregory Bociek, MD, James Olen Armitage, MD, Julie M Vose, MD

Blood (2017) 130 (Supplement 1): 4039.

https://doi.org/10.1182/blood.V130.Suppl_1.4039.4039

Published: 2017

Journal Articles

Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL)

Avyakta Kallam, MBBS, James O. Armitage, MD, Baojiang Chen, PhD, Julie M. Vose, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 5949.

https://doi.org/10.1182/blood.V128.22.5949.5949

Published: 2016

Journal Articles

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Jayadev Manikkam Umakanthan, MBBS, Lori J. Maness, MD, Jiangtao Luo, Avyakta Kallam, MBBS, James O. Armitage, MD, Philip Bierman, MD, Julie M. Vose, MD, R. Gregory Bociek, MD, Matthew Lunning, DO, Krishna Gundabolu, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 5154.

https://doi.org/10.1182/blood.V128.22.5154.5154

Published: 2016

Journal Articles

Risk of 30-Day Mortality and Its Association with Health System and Socioeconomic Factors in Diffuse Large B Cell Lymphoma (DLBCL)

Avyakta Kallam, MBBS, Julie M Vose, MD, Baojiang Chen, PhD, James O. Armitage, MD, Vijaya R. Bhatt, MD

Blood (2016) 128 (22): 2347.

https://doi.org/10.1182/blood.V128.22.2347.2347

Published: 2016

NARROW

Academic Centers Are Associated with Improved Survival Outcomes in High Risk Diffuse Large B-Cell Lymphoma Patients

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL)

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Risk of 30-Day Mortality and Its Association with Health System and Socioeconomic Factors in Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Academic Centers Are Associated with Improved Survival Outcomes in High Risk Diffuse Large B-Cell Lymphoma Patients

Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL)

Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)

Risk of 30-Day Mortality and Its Association with Health System and Socioeconomic Factors in Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only